

ZYMIQ

Smart Enzyme Technology



Quarterly report Q3

July - Sept 2025

Focus on new agreements

During the quarter, we strengthened our market position through new strategic partnerships and distribution agreements. These investments will constitute important steps towards a broader international presence and create a solid foundation for ZymIQ's continued expansion.

1 Jan – 30 Sep 2025

- Net sales increased by 53% to SEK 1,546 thousand (1,012)
- Loss after tax amounted to SEK -6,242 thousand (-8,343)
- Earnings per share amounted to SEK -0.72 (-1.04)
- Cash and cash equivalents amounted to SEK 1,960 thousand (1,018)

1 July – 30 Sept 2025

- Net sales amounted to SEK 400 thousand (268)
- Loss after tax amounted to SEK -1,030 thousand (-3,008)
- Earnings per share amounted to SEK -0.12 (-0.35)

Significant events during the reporting period

- Premiere of ZymIQ's dental care products in Asia – new exclusive distribution agreements have been signed with the Malaysian company Pahang Pharmacy Sdn Bhd and the Thai company Thai company Union Medical (Thailand) Co.
- Exclusive distribution agreements for Kalzyme have been signed with KM Vet Pharm Sdn Bhd. in Malaysia and with the Thai company Vet AgriTech CO Ltd.
- A new collaboration has been initiated with the Zoofamiljen store chain in Sweden for the distribution of all Kalzyme products.
- Dr. Mats Clarsund spoke at the Dent2Health Conference in Malmö about ZymIQ's enzyme technology linked to oral health in front of dentists and researchers.

Significant events after the reporting period

- The European Patent Office (EPO) has announced that no opposition has been filed against the company's granted patents EP4380549 linked to ViruPrev.
- ZymIQ has signed a new agreement with last year to drive global expansion and product development.
- Jörgen Thunholm has been recruited as Supply Chain Director ahead of the global launch.
- A reseller agreement for CombatClean Dental Enzyme Tab and K9 Dental Enzyme Spray has been signed with Kynotec GmbH for Austria, Switzerland and Germany.
- The production of our toothbrush tablet has been successfully moved to Sweden, where the test production has been approved, and the cost target has been achieved.

"Our business model is ready to be scaled up,
which is shown not least by the new distribution agreements."

Michael Edelfborg Christensen,
CEO, ZymIQ Technology



Message from the CEO



The third quarter marks a milestone in ZymIQ's journey—not only scientifically, but also personally. When the pandemic struck, I was in Bergamo, Italy. It was an experience that changed everything. Out of that crisis came a new direction: to build a company that truly makes a difference for both people and animals.

ZymIQ is the result of that vision. During the quarter, we have taken decisive steps toward realizing our scientific potential. Our technology has proven capable of preventing viruses from infecting and reinfecting—a breakthrough we have long worked on quietly to secure patent protection. Now the time is right to take this forward.

In the fight against bacteria, we have gone even further. Two separate in-vivo studies confirm that our evolutionary theory works. We have successfully engineered enzymes that target multidrug-resistant bacteria in hard-to-reach areas—quickly and effectively. The results are groundbreaking and are expected to be published in a leading scientific journal, further strengthening our position ahead of upcoming business negotiations.

Our business model is ready to scale, as evidenced by the new distribution agreements. We are working patiently to find the right international partners, and this is now gaining real momentum. When scientific progress is combined with strong user reviews—where our products are described as outstanding and truly effective—the leverage effect becomes significant.

Together with our new Supply Chain Director, Jörgen Thunholm, we have successfully relocated the production of our tooth-cleaning tablet to Sweden. This has been an extensive process involving technical transfer in accordance with ISO 9001 principles. I am proud to announce that the first test production has passed all laboratory tests with approved results. We can now manufacture the tablets at the cost level we targeted at the very beginning of the project.

Together, we are building a company that not only redefines health, hygiene, and sustainability—but is also ready to scale globally, launch new products, and drive long-term growth throughout 2026.

With confidence,

Michael Edelborg Christensen

CEO, ZymIQ Technology AB

Business Overview

About the Company

ZymlQ is an innovative Life Science group, founded in 2020, by scientists, veterinarians and entrepreneurs.



ZymlQ Technology AB focuses on smart enzyme technology in health products intended for both humans and animals.

ZymlQ Biopharma AB is a wholly owned subsidiary that develops the next generation of antimicrobial products using enzyme and phage technology that are more effective and less harmful than traditional treatments. In this way, ZymlQ is fighting the global threat of increased antibiotic resistance by developing new solutions that can potentially replace or complement future antibiotic treatments.

ZymlQ is headquartered at Medicon Village in Lund, Sweden, and has offices in Virginia, USA, as well as representative offices in Singapore and Malaysia.

Introduction to the Company's operations

ZymlQ has developed two unique research platforms to prevent current infections. ZymlQ's first platform protects healthy skin and mucous membrane, while the second platform fights ongoing current bacterial infections. Here, the enzymes act as high-precision tools that can target unwanted pathogens, while keeping the microbiome healthy and intact. With the potential for unique synergy effects, the platforms have the potential to deliver products that can replace conventional antibiotic treatment and thereby reduce the risk of antibiotic resistance.

In addition to advanced research, ZymlQ primarily develops enzyme-based oral care products for humans and animals. DentaPrev (www.dentaprev.com) is an innovative brand in oral care that uses enzymes to prevent malignant bacteria from causing plaque, tartar and bad breath. Kalzyme (www.kalzyme.com), for dental and skin care in animals, prevents microbial adhesion and irritation to the skin and mucous membranes and accelerates the healing process. ZymlQ also has a partnership with the high-profile skincare brand fjör (www.fjor.life), which exclusively uses the company's technology platforms for the development of new products.



First picture above: Signing a contract with the Malaysian company Pahang Pharmacy Sdn Bhd.
Second picture above: Mats Clarsund presenting at Dent2Health with a focus on dentists.


Financial overview

The third quarter was characterized by a steadily increasing interest and a growing awareness among Swedish pet owners for our Kalzyme products. The agreement with the Zoo family on the west coast is a receipt for this. On the human side, we see that consumers have started to find our products at online pharmacies, which has resulted in some orders from there.

At the same time, test orders for the CombatClean concept continue to come in – during the quarter we received orders from Slovakia, Germany and Austria. Even if the volumes are small, it indicates that the interest continues. These test orders are partially discounted, which negatively affects the Gross Margin. However, it is a deliberate choice so that we can get to the market quickly, without lengthy negotiations on prices and other conditions. To improve the margin, we decided to move production home to Sweden during the quarter. This means that the gross margin improves significantly in the long term. The variations on the cost side are largely due to the phases of the various development projects that are carried out, which means that operating profit fluctuates between the different quarters.


Quarterly earnings development

**Net Sales Q1-Q3 2025
by Brand**



■ DentaPrev (tab+spray) ■ Kalzyme ■ Fjör ■ CombatClean (tab+K9)

**Net Sales Q1-Q3 2025
by Geographic Area**



■ Europe ■ Asia ■ US

Quarterly financial performance

All amounts in SEK thousand	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Net sales	400	334	812	269	268	328	416
Gross profit/loss	151	277	240	44	213	157	340
Gross margin in %	38%	83%	30%	16%	79%	48%	82%
Operating profit/loss	-1 029	-3 148	-2 104	-2 764	-2 942	-3 136	-2 205
Profit/loss for the period	-1 030	-3 149	-2 063	-2 610	-3 008	-3 157	-2 179
Cash flow	1 072	-1 369	-932	2 171	-3 951	4 245	-427



DentaPrev

DentaPrev offers gentle and effective dental care that improves oral hygiene with the help of enzymes. With high-quality ingredients and enzymes, DentaPrev helps fight plaque, tartar, and bad breath. The portfolio includes dental spray and enzyme tablets.



Clean Teeth Enzyme Tab

Clean Teeth Enzyme Tab is a new revolutionary tablet that contains a powerful enzyme blend. Clinical studies have shown that these lozenges can significantly reduce plaque while balancing the microbiome. Clean Teeth Enzyme Tab is equivalent to about 60 seconds of brushing when taking three tablets per day.

Clean Teeth Enzyme Tab is thus an optimal solution for the elderly, who have difficulty brushing their teeth mechanically. It's also perfect for people on the go, anytime and anywhere, where access to a toothbrush, water or rinsing is lacking, or for those who simply want to take their oral hygiene to the next level. The product has been developed in collaboration with one of the world's leading enzyme companies.



DentaPrev Dental Spray

DentaPrev Dental Spray is used to clean teeth and gums, maintain good oral hygiene, and freshen your breath throughout the day. The product improves your oral hygiene by creating a multifunctional barrier that prevents the adhesion of bacteria. At the same time, the oral microbiome is balanced.

The unique design of the bottle is adapted to the user's needs, where it should be easy and convenient to improve both their own and others' oral hygiene. The spray is intended for children, adults and the elderly for smooth, effective and gentle oral care.

Status DentaPrev

During the quarter, DentaPrev took several important steps forward in international expansion. We have signed agreements with new distributors in Asia, where major players have joined in both Thailand and Malaysia. These agreements strengthen our presence in two of the region's most important markets and create the conditions for increased growth in oral health.

Work is now also underway to develop a new, more consumer-friendly and affordable packaging for Enzyme Tab to enable sales in larger volumes. The goal is an attractive package that is easy to carry around. Initially, the tablet will be launched with mint flavour and in the next step, more flavour variants are planned. The primary target group is young people to begin with, and the launch will be supported through social media, where we plan to collaborate with an experienced agency in the field.

In order to reduce production costs and at the same time gain greater control over quality, delivery reliability and flexibility, production is also being moved to Sweden. Together with our new manufacturer, we have now carried out a first test production, where the results regarding stability and enzyme activity showed very good quality. The next step will be to produce a three-pack for the upcoming launch event.

At the Dent2Health conference in Malmö, our co-founder, Dr. Mats Clarsund, participated, where he spoke about the connection between oral and systemic health. The event brought together dentists, researchers and industry colleagues who share our commitment to preventive care and innovative solutions.

As a complement to the existing DentaPrev spray, which has a more medical device design, work is now also underway to develop a spray in a more aesthetically pleasing and cosmetic packaging - designed to be easy to use and take with you, for



example in a restaurant. DentaPrev will thus have a clearer lifestyle profile with Asia as its first primary market and with the intention of launching it under a separate brand.

CombatClean



The CombatClean brand has been developed to provide enzyme-based health products specifically adapted for military personnel and emergency services. Currently, the range includes Clean Teeth Enzyme Tab and Kalzyme K9 Dental Spray for service dogs. The ambition is to also include DentaPrev Dental Spray in the range.

Clean Teeth Enzyme Tab

The Clean Teeth Enzyme Tab focuses on the military and Armed Forces where dental disease is one of the most common non-combat-related injuries during military operations, with 150-200 acute dental cases per 1,000 people annually in active-duty forces. Dental problems often lead to staff having to be evacuated from their assignments, resulting in loss of time and strain on resources and negatively affecting operational readiness. CombatClean can play an important role in this by offering efficient and flexible dental care for the personnel out in the field.



K9 Dental Enzyme Spray

Keeping a dog's teeth clean and free of plaque is no easy task. Traditional toothbrushing is often a challenge, and the high cost of veterinary dentistry can add up quickly. Even worse, poor oral health can impair a K9's overall performance. That's why we now also offer K9 Dental Enzyme Spray, specifically designed for service dogs.

Status CombatClean

CombatClean has participated in several new trade fairs around Europe and held lectures at military events. The concept of ZymiQ Field Hygiene is under further development, and new exhibition material is being developed to more clearly communicate the message.

In line with DentaPrev Clean Teeth, the production of CombatClean Dental Enzyme Tab is also being moved to Sweden to increase cost efficiency. New packaging for daily and weekly rations is under development. To the left, the latest draft of the packaging layout.





Kalzyme

Kalzyme is developed by veterinarians and animal health scientists. Kalzymes' unique enzyme technology is specifically developed to strengthen the natural defenses and reduce the risk of growth of harmful bacteria by breaking down biofilms. The product portfolio includes three products in the form of Dental Spray, Dermal Spray and Dermal Gel. Additional products are under development. Kalzyme is currently available for sale in the Southeast Asian markets and in Sweden and has been launched for veterinarians in the US in the fall of 2024.



Kalzyme Dental Spray

Kalzyme Dental Spray is a dental spray for dogs and cats. Dental Spray helps to counteract plaque and tartar build-up while supporting a healthy bacterial flora in the mouth and providing fresh breath.

Kalzyme Dermal Spray & Gel

Kalzyme Dermal Spray and Gel create a soothing protective film around skin irritations, hotspots, redness and itching. At the same time, the skin is exfoliated and moisturized.

Status Kalzyme

During the quarter, ZymiQ took several important steps in its international growth journey. All Kalzymes products are now available through Zoofamiljen, a well-known Swedish retailer with stores in Kungsbacka, Varberg, Kungälv, Vänersborg and Strömstad. The Zoo family is known for its strong commitment to animal health and customer service, making the collaboration a valuable step in strengthening Kalzymes' presence in the Swedish market and increasing accessibility for pet owners seeking innovative and reliable care solutions.

ZymiQ has also continued its expansion in Asia by signing exclusive

distribution agreements for Kalzyme with Vet AgriTech in Thailand and KM Vet Pharm Sdn Bhd in Malaysia. Both collaborations are based on several years of tests and evaluations together with veterinarians and pharmacies in the region. These agreements mark important milestones in the company's global expansion and confirm the strong international interest in ZymiQ's enzyme-based products.



Image above: Signing a contract with KM Vet Pharm Sdn Bhd in Malaysia



Partnership with fjör

ZymlQ is an innovative skincare brand that uses ZymlQ's enzyme technology to strengthen the skin barrier and promote microbial diversity. The product range offers Hydrolytic serum, moisturizer and body lotion. Fjör has received international attention in Vogue, Financial Times, The Handbook, Esquire and Stylist Magazine, among others.



Status fjör

ZymlQ has now signed a new agreement with fjör to drive global expansion and product development. During the 36-month agreement, ZymlQ will manufacture last year's entire product portfolio, lead the development of new products and be guaranteed a fixed revenue during the period.

"Our collaboration is built on a shared commitment to cutting-edge science, integrity, and purpose. Together, we have created something that goes beyond skincare; products that reflect years of research, mutual trust and a belief in advancing how we take care of our skin," says Natalie Enslöw, founder and CEO of fjör.

"The fact that Fjör now wants to scale up its business shows that its products are appreciated by customers around the world. I am delighted with their success and expansion," says Michael Edelborg Christensen, CEO of ZymlQ.





Financial information

Company information

ZymIQ Technology AB (publ), corporate identity number 559279–3631, is a Swedish-registered limited liability company with its registered office in Lund, Sweden, and which is the parent company of the ZymIQ Group. The address of the head office is Scheeletorget 1, 223 63 Lund. Wholly owned subsidiaries are ZymIQ Biopharma AB, Lund, Sweden and ZymIQ Animal Health LLC, Virginia, USA. The company is also represented through offices in Singapore and Malaysia.

Share

ZymIQ Technology AB (publ) intends to be listed on Nasdaq First Growth Market. ISIN code: SE0016074306.

The number of shares at the end of the period was 8,880,736. All shares are of the same class and have the same voting rights.

Scope of the report

This year-end report covers the period from 1 July 2025 to 30 September 2025. All information in the report relates to the ZymIQ Group.

Organization

At the end of the period, the Group had 10 employees, of which 7 were women and 3 men. The number of consultants is 1-2.

Research and development

The development work is run in-house in collaboration with consultants and external clinics. The development work is focused on new development and further refinement of the current product portfolio.

Disputes

ZymIQ Technology is not a party to any legal dispute or arbitration. Nor is the Board aware of any circumstances that could lead to any such legal process being imminent.

Insurance

ZymIQ Technology has customary business insurance that also includes product liability coverage. The insurance cover is subject to continuous review. The Board of Directors assesses that the business insurance is adapted to the current scope of the business.

Risk factors

ZymIQ Technology was formed in 2020. The company's contacts with both customers and suppliers are relatively short. A short history of operations can be expected to lead to an increased sensitivity to changes in the outside world. The short operating history also makes it more difficult to evaluate growth power and profitability targets. The risks that are primarily assessed to affect the company can be divided into market-related and company-specific risks. The market-related risks mainly consist of uncertainty regarding capital raising, market developments, political climate, competition, and suppliers and production. In addition to the short history, the largest company-specific risks are also found in clinical studies, organizational development, development costs, product liability and intellectual property rights.

Conditions for continued operation

This financial information has been prepared based on the going concern assumption. ZymIQ Technology has historically reported losses. In preparing the communiqué, management has based its assumptions on existing cash and cash equivalents, increased sales and the possibility of other financing. When estimating future expenses, management has taken into account that certain expenses are under management's control and can thus be eliminated or postponed to the future. Management is aware that there is uncertainty in the estimation of future cash flows as well as uncertainty in the financing of operations.

If ZymIQ Technology is unable to continue to operate the business for any reason, it may affect the Group's ability to realize the carrying amount of its assets, especially related to retained expenses for development work, as well as to pay debts at a normal pace and to the amounts recorded in the Group's quarterly report.

Annual report

The Annual Report for 2024 is available at the company.

Agm

The 2025 Annual General Meeting was held on May 15 in Lund. The protocol is available at ZymIQ Technology AB.

Accounting principles

This report has been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board's general guidelines. The accounting policies and calculation methods applied are consistent with the accounting policies used in the preparation of the last annual report.

Auditor review

This report has not been reviewed by the company's auditor.

ZymIQ Technology AB
Lund, 14 November 2025

Board

*Jonas Forsberg, Magnus Steen, Nicklas Persson
Rickard Ånell, Göran Strömberg*

QUESTIONS ABOUT THE REPORT WILL BE ANSWERED BY

Michael Edelborg Christensen, CEO, ZymIQ Technology AB

Tel: 0727-144 166

Mail: michael.christensen@zymiq.com

Summary of the income statement – Group

Consolidated Income Statement in Summary

All amounts in SEK thousand	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Operating income					
Net sales	400	268	1 546	1 012	1 281
Cost of goods sold	-249	-55	-1 028	-427	-527
Gross profit	151	213	518	585	754
External expenses	-753	-1 440	-4 007	-4 136	-7 782
Staff expenses	-482	-1 780	-3 317	-4 481	-4 906
R&D Expenses	-1 903		-2 719	-1 627	-2 652
Capitalized development expenditure	1 903		2 719	1 627	2 652
Other operating income	55	68	531	136	922
Other operating expenses	0	-3	-6	-386	-35
Operating profit/loss	-1 029	-2 942	-6 281	-8 282	-11 047
Profit/loss from financial items	0				
Interest income and similar profit/loss items	0	2	43	64	163
Interest expenses and similar profit/loss items	-1	-68	-4	-125	-70
Profit/loss after financial items	-1 030	-3 008	-6 242	-8 343	-10 954
Tax expenses	-	-	-	-	-
Profit/loss for the period	-1 030	-3 008	-6 242	-8 343	-10 954

Per share data	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Earnings per share, SEK (basic and diluted)	-0,12	-0,35	-0,72	-1,04	-1,35
Equity per share, SEK	2,38	1,29	2,15	1,37	1,29
Equity-asset ratio, %	80%	84%	80%	84%	81%
Number of outstanding shares	8 880 736	8 556 200	8 880 736	8 556 200	8 556 250
Average number of outstanding shares	8 880 736	8 556 250	8 700 466	8 003 472	8 141 667

Definitions of financial ratios

Earnings per share. Profit/loss for the period divided by average weighted number of shares

Equity-asset ratio. Equity divided by total assets.

Equity per share. Equity divided by number of shares at the end of the period.

Quarterly financial performance

All amounts in SEK thousand	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Net sales	400	334	812	269	268	328	416
Gross profit/loss	151	277	240	44	213	157	340
Gross margin in %	38%	83%	30%	16%	79%	48%	82%
Operating profit/loss	-1 029	-3 148	-2 104	-2 764	-2 942	-3 136	-2 205
Profit/loss for the period	-1 030	-3 149	-2 063	-2 610	-3 008	-3 157	-2 179
Cash flow	1 072	-1 369	-932	2 171	-3 951	4 245	-427



Consolidated balance sheet in brief

Consolidated Balance Sheet in Summary

All amounts in SEK thousand	2025-09-30	2024-09-30	2025-06-30	2024-12-31
Assets				
Intangible assets	19 246	6 631	17 423	16 977
Property, plant & equipment	274	219	274	205
Inventories	1 829	1 156	1 846	2 202
Trade receivables	1 846	536	1 587	957
Other receivables	1 406	3 536	1 410	1 139
Cash and cash equivalents	1 960	1 018	888	3 189
Total assets	26 561	13 096	23 428	24 669
Equity and liabilities				
Equity	21 174	11 055	19 090	19 988
Interest-bearing liabilities, Long-term			0	0
Interest-bearing liabilities, Short-term	2 950	5	2 250	2 250
Trade payables	868	380	815	919
Other liabilities	1 569	1 656	1 273	1 512
Total equity and liabilities	26 561	13 096	23 428	24 669

Consolidated statement of changes in equity

All amounts in SEK thousand	2025-09-30	2024-09-30	2025-06-30	2024-12-31
Opening balance	19 988	6 959	19 988	6 726
New share issues	7 428	12 672		25 538
New Issue- Not reg.ShareCapital			4 314	-
Costs of new share issues				-
Profit/loss for the period	-6 242	-8 343	-5 212	-10 954
Other comprehensive income for the period		-233		-1 322
Closing balance	21 174	11 055	19 090	19 988



Cash flow statement in brief – Group

Cash Flow Analysis in Summary

All amounts in SEK thousand	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Profit/loss after financial items	-1 030	-3 008	-6 242	-8 343	-10 954
Adjustments for non-cash items	80	1	380	358	-659
Tax paid	-	-	-	-	-
Cash flow from operating activities before changes in working capital	-950	-3 007	-5 862	-7 985	-11 613
Changes in working capital	111	-3 246	-777	-3 194	-1 869
Cash flow from operating activities	-839	-6 253	-6 639	-11 179	-13 482
Capitalization of development expenditure	-1 881	-	-2 571	-1 627	-2 265
Acquisition/disposal of intangible assets	-	-	-	-	-10 000
Acquisition/disposal of property, plant & equipment	-22	-	-147	-4	-3
Acquisition/disposal of financial assets	-	-	-	0	0
Cash flow from investing activities	-1 903	0	-2 718	-1 631	-12 268
New share issue	3 114	2 302	7 428	12 672	25 538
Transaction costs attributable to new share issue	-	-	-	-	-
Change in bank overdraft facilities	700	-	700	5	2 250
Amortization in bank overdraft facilities	-	-	-	-	-
Cash flow from financing activities	3 814	2 302	8 128	12 677	27 788
Total cash flow for the period	1 072	-3 951	-1 229	-133	2 038
Cash and cash equivalents at start of period	888	4 969	3 189	1 151	1 151
Cash and cash equivalents at end of period	1 960	1 018	1 960	1 018	3 189

Parent company's income statement

Income Statement - Parent Company

All amounts in SEK thousand	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Operating income					
Net sales	400	268	1 540	1 012	1 302
Cost of goods sold	-220	-55	-962	-427	-426
Gross profit	180	213	578	585	876
External expenses	-732	-1 358	-3 905	-4 054	-4 256
Staff expenses	-482	-1 780	-3 036	-4 481	-6 423
R&D Expenses	-1 903		-2 719	-1 627	-2 652
Capitalized development expenditure	1 903		2 719	1 627	2 652
Other operating income	55	68	242	136	186
Other operating expenses	0	-3	-6	-386	-393
Operating profit/loss	-979	-2 860	-6 127	-8 200	-10 010
Interest income and similar profit/loss items	0	2	43	64	163
Interest expenses and similar profit/loss items	-1	-68	-2	-125	-125
Profit/loss after financial items	-980	-2 926	-6 086	-8 261	-9 972
Tax expenses	-	-	-	-	-
Profit/loss for the period	-980	-2 926	-6 086	-8 261	-9 972

Parent company's balance sheet

Balance Sheet - Parent Company

All amounts in SEK thousand	2025-09-30	2024-09-30	2025-06-30	2024-12-31
Assets				
Intangible assets	9 296	6 631	7 529	7 027
Property, plant & equipment	274	219	218	205
Financial assets	10 000	0	10 000	10 000
Inventories	1 053	1 156	1 069	1 428
Trade receivables	1 846	536	1 587	832
Receivables from group companies	2 607	2 284	2 907	3 213
Other receivables	1 406	1 252	1 410	808
Cash and bank balances	1 884	1 018	458	2 717
Total assets	28 366	13 096	25 178	26 230
Equity and liabilities				
Equity	22 990	11 137	20 856	21 647
Interest-bearing liabilities, longterm	0	0	0	0
Current interest-bearing liabilities	3 250	0	2 250	2 250
Liabilities to group companies	0	0	0	0
Trade payables	868	380	815	919
Other liabilities	1 258	1 579	1 257	1 414
Total equity and liabilities	28 366	13 096	25 178	26 230